Cost-Benefit Of Early Access To NSCLC Drugs Evaluated In JAMA Study
Executive Summary
Researchers from University of California and Novartis present a framework for evaluating the social benefits of early access to new treatments on the basis of progression-free survival.
You may also be interested in...
Farydak Confirmatory Trial To Come Years After Accelerated Approval
Despite the agency’s preference that confirmatory trials generally be under way at the time of accelerated approval, Novartis’ panobinostat Phase III trial isn’t expected to begin for approximately three years.
Novartis’ Zykadia Sets New “Breakthrough” Speed Record For NME Review
FDA grants accelerated approval to ceritinib following a four-month review. The ALK inhibitor is indicated for non-small cell lung cancer patients who have progressed on or are intolerant of Pfizer’s Xalkori.
Pharma Gets 340B Appeals Court Victory But More Decisions Are Pending; Will Congress Step In?
Third Circuit is first of three federal appeals courts to issue a decision in multiple lawsuits over drug companies’ 340B contract pharmacy restrictions, which have led to conflicting lower court rulings on whether such restrictions are unlawful.